Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.35 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.35 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.34 |
| ▸ | USP2 | O75604 | 1/20 | 0.33 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.33 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.33 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | BTK | Q06187 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27207278 | 0.80 | HSD17B10 (0.40) | HSD17B10CHRM2CHRM1CHRM3SMN1; SMN2 | |
| SCHEMBL27203890 | 0.80 | HSD17B10 (0.40) | HSD17B10CHRM2CHRM1CHRM3SMN1; SMN2 | |
| SCHEMBL22320894 | 0.79 | HSD17B10 (0.40) | HSD17B10CHRM2CHRM1CHRM3SMN1; SMN2 | |
| SCHEMBL35211488 | 0.79 | HSD17B10 (0.40) | HSD17B10CHRM2CHRM1CHRM3SMN1; SMN2 | |
| SCHEMBL21996489 | 0.76 | NR1H2 (0.41) | HSD17B10CHRM2CHRM1CHRM3SMN1; SMN2 | |
| SCHEMBL22047153 | 0.76 | NR1H2 (0.41) | HSD17B10CHRM2CHRM1CHRM3SMN1; SMN2 | |
| SCHEMBL29149056 | 0.76 | HSD17B10 (0.41) | HSD17B10CHRM2CHRM1CHRM3SMN1; SMN2 | |
| SCHEMBL883020 | 0.76 | HSD17B10 (0.38) | HSD17B10CHRM2CHRM1CHRM3SMN1; SMN2 | |
| SCHEMBL29148977 | 0.76 | HSD17B10 (0.41) | HSD17B10CHRM2CHRM1CHRM3SMN1; SMN2 | |
| SCHEMBL21996584 | 0.76 | ELANE (0.43) | SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12194023-B2 | Compositions and methods for modular control of bioorthogonal ligation | THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK (US) | 2025-01-14 | — | — | US | disclosed |
| US-20220218661-A1 | COMPOSITIONS AND METHODS FOR MODULAR CONTROL OF BIOORTHOGONAL LIGATION | THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK (US) | 2022-07-14 | — | — | US | disclosed |
| WO-2020113077-A9 | COMPOSITIONS AND METHODS FOR MODULAR CONTROL OF BIOORTHOGONAL LIGATION | THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK (US) | 2020-08-13 | — | — | WO | disclosed |
| WO-2020113077-A9 | COMPOSITIONS AND METHODS FOR MODULAR CONTROL OF BIOORTHOGONAL LIGATION | THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK (US) | 2020-08-13 | — | — | WO | disclosed |
| WO-2020113077-A1 | COMPOSITIONS AND METHODS FOR MODULAR CONTROL OF BIOORTHOGONAL LIGATION | THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK (US) | 2020-06-04 | — | — | WO | disclosed |
| WO-2020113077-A1 | COMPOSITIONS AND METHODS FOR MODULAR CONTROL OF BIOORTHOGONAL LIGATION | THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK (US) | 2020-06-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220218661-A1 | COMPOSITIONS AND METHODS FOR MODULAR CONTROL OF BIOORTHOGONAL LIGATION | CBR3, C1R, CBR1 | HSD17B10 2415/4885CHRM2 237/4885CHRM1 260/4885 |
| US-12194023-B2 | Compositions and methods for modular control of bioorthogonal ligation | CBR3, C1R, CBR1 | HSD17B10 2415/4885CHRM2 237/4885CHRM1 260/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.